pros in papillon trial: amivantamab chemo for egfr exon 20 nsclc
Published 6 months ago • 97 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
2:07
papillon: amivantamab plus chemotherapy in nsclc with egfr exon 20 insertions
-
1:27
papillon phase iii primary results: amivantamab chemo vs chemo in egfr exon 20 nsclc
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
3:58
current treatments and challenges for patients with egfr exon 20 insertion-positive nsclc
-
3:16
mariposa-2: second interim os of amivantamab and chemotherapy in egfr-m nsclc
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
0:56
the clinical impact of amivantamab and chemotherapy in egfrm nsclc
-
1:36
chrysalis: amivantamab for egfr exon 20 insertion mutant nsclc
-
0:59
new standard of care treatment for egfr exon 20 non-small cell lung cancer | dr. alexander spira
-
4:47
treating non–small cell lung cancer with an egfr exon 20 insertion
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
32:15
a visual exploration of new targeted therapies for egfr exon 20 insertions in nsclc
-
6:07
amivantamab and mobocertinib for egfr exon-20 disease - lung cancer video library
-
3:50
amivantamab plus lazertinib is a new standard for egfr-mutant nsclc
-
0:53
treatments for patients with nsclc carrying egfr exon 20 insertions
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
2:04
mariposa-2: amivantamab chemo (± lazertinib) vs chemo in egfr-mutated nsclc post-osimertinib
-
4:27
amivantamab shows robust efficacy in post-platinum therapy patients with egfr ex20ins nsclc